How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

Blood

Volumn 125, Issue 8, 2015, Pages 1226-1235

  Uldrick, Thomas S ^a   Little, Richard F ^a,b  

^a Center for Cancer Research   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BLEOMYCIN; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; FILGRASTIM; FLUORODEOXYGLUCOSE F 18; LAMIVUDINE; MELPHALAN; PEGFILGRASTIM; PREDNISONE; TENOFOVIR; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMORBIDITY; DRUG DOSE REDUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATHOLOGY; PNEUMOCYSTIS PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPH NODE METASTASIS; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; HIV INFECTIONS; HIV-1; HODGKIN DISEASE; HUMANS; LYMPHATIC METASTASIS; MALE; VINBLASTINE;

EID: 84923336103     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-551598     Document Type: Article

References (88)

1. Calabresi A, Ferraresi A, Festa A, et al; Brescia HIV Cancer Study Group. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med. 2013;14(8):481-490.
2. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786-3791.
3. Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23(2): 274-281.
4. Bohlius J, Schmidlin K, Boué F, et al; Collaboration of Observational HIV Epidemiological Research Europe. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4 T-cell lymphocytes. Blood. 2011;117(23): 6100-6108.
5. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8): 2339-2344.
6. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9): 753-762.
7. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28(6):881-890.
8. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153(7):452-460.
9. Wiggill TM, Mantina H, Willem P, Perner Y, Stevens WS. Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. J Acquir Immune Defic Syndr. 2011; 56(5):460-466.
10. Little RF. AIDS-related non-Hodgkin's lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy. Leuk Lymphoma. 2003; 44(Suppl 3):S63-S68.
11. Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematology (Am Soc Hematol Educ Program). 2013;2013:382-388.
12. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003; 101(12):4653-4659.
13. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIVassociated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221-1229.
14. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001; 285(13):1736-1745.
15. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16(8):1155-1161.
16. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13(7): 1758-1767.
17. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol. 2004;125(4):455-462.
18. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
19. Gotti D, Danesi M, Calabresi A, et al; Brescia HIV Cancer Study Group. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy. AIDS Patient Care STDS. 2013;27(5): 259-265.
20. Lanoy E, Rosenberg PS, Fily F, et al; FHDHANRS CO4. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118(1):44-49.
21. Kowalkowski MA, Mims MA, Day RS, Du XL, Chan W, Chiao EY. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: a cohort study of HIVinfected male veterans. Cancer Epidemiol. 2014; 38(4):386-392.
22. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117(5):1089-1096.
23. Kowalkowski MA, Mims MP, Amiran ES, Lulla P, Chiao EY. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS ONE. 2013;8(10):e77409.
24. Gopal S, Patel MR, Achenbach CJ, et al. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis. 2014;59(2):279-286.
25. Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121(5):727-738.
26. Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virusharboring cells in Hodgkin's disease. Blood. 1992; 80(2):484-491.
27. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495-1505.
28. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood. 1999;93(7):2319-2326.
29. Herndier BG, Sanchez HC, Chang KL, Chen YY, Weiss LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am J Pathol. 1993;142(4): 1073-1079.
30. Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J Pathol. 1992;167(4): 381-384.
31. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991; 337(8737):320-322.
32. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA. 1993;90(19):9150-9154.
33. Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007;110(10):3715-3721.
34. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virusencoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173(1):195-204.
35. Morales O, Mrizak D, Francois V, et al. Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. Br J Haematol. 2014;166(6):875-890.
36. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009;113(12): 2765-2775.
37. Steidl C, Diepstra A, Lee T, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120(17):3530-3540.
38. Scott DW, Chan FC, Hong F, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2013;31(6):692-700.
39. Kiyasu J, Aoki R, Tanaka PY, et al. FOXP3(1) regulatory and TIA-1(1) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma. Pathol Int. 2012;62(2):77-83.
40. Bosch Príncep R, Lejeune M, Salvadó Usach MT, Jaén Martínez J, Pons Ferré LE, Alvaro Naranjo T. Decreased number of granzyme B1 activated CD81 cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol. 2005;84(10): 661-666.
41. Koulis A, Trivedi P, Ibrahim H, Bower M, Naresh KN. The role of the microenvironment in human immunodeficiency virus-associated classical Hodgkin lymphoma. Histopathology. 2014;65(6):749-756.
42. Hartmann S, Jakobus C, Rengstl B, et al. Spindleshaped CD1631 rosetting macrophages replace CD41 T-cells in HIV-related classical Hodgkin lymphoma. Mod Pathol. 2013;26(5):648-657.
43. Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med. 1986;314(14):874-879.
44. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006;66(11): 5716-5722.
45. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339-2346.
46. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
47. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011; 96(2):269-276.
48. Tan KL, Scott DW, Hong F, et al. Tumorassociated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120(16):3280-3287.
49. Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol. 1999;10(2):189-195.
50. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
51. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20(7):985-993.
52. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Wholebody positron emission tomography in patients with HIV-1 infection. Lancet. 2003; 362(9388):959-961.
53. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, Van De Wiele C. FDG uptake in lymph-nodes of HIV1 and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging. 2010; 54(6):698-703.
54. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-3058.
55. Fardet L, Lambotte O, Meynard JL, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS. 2010;24(9):1299-1306.
56. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf. Accessed June 1, 2014.
57. Bharti AR, Letendre SL, Wolfson T, et al. Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. J Clin Virol. 2011; 52(4):328-332.
58. Errante D, Tirelli U, Gastaldi R, et al; The Italian Cooperative Group on AIDS and Tumors (GICAT). Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer. 1994;73(2):437-444.
59. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colonystimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24(5):444-450.
60. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007; 18(2):376-380.
61. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012; 30(33):4111-4116.
62. Hentrich M, Berger M, Wyen C, et al. Stageadapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117-4123.
63. Xicoy B, Ribera JM, Miralles P, et al. Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. Leuk Lymphoma. 2009;50(10):1718-1720.
64. Ezzat HM, Cheung MC, Hicks LK, et al. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virusassociated Hodgkin lymphoma. Leuk Lymphoma. 2012;53(12):2390-2396.
65. Corona G, Vaccher E, Spina M, Toffoli G. Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma. AIDS. 2013; 27(6):1033-1035.
66. Meyer RM, Gospodarowicz MK, Connors JM, et al; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
67. Viviani S, Zinzani PL, Rambaldi A, et al; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-212.
68. Meyer RM, Hoppe RT. Point/counterpoint: earlystage Hodgkin lymphoma and the role of radiation therapy. Blood. 2012;120(23):4488-4495.
69. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS. 1998;12(1):65-74.
70. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(4): 422-428.
71. Gérard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17(1):81-87.
72. Ribera JM, Navarro JT, Oriol A, et al. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. AIDS. 2002; 16(14):1973-1976.
73. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
74. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002; 34(8):1115-1121.
75. Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60(2):150-157.
76. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105(2):874-878.
77. Spitzer TR, Ambinder RF, Lee JY, et al. Dosereduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14(1):59-66.
78. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306-1313.
79. Balsalobre P, Díez-Martín JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009; 27(13):2192-2198.
80. Bayraktar UD, Ramos JC, Petrich A, et al. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012;53(12): 2383-2389.
81. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26(7):1027-1032.
82. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24): 3746-3752.
83. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59.
84. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99(6):1107-1113.
85. Hutchings M, Kostakoglu L, Zaucha JM, et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol. 2014;32(25): 2705-2711.
86. Okosun J, Warbey V, Shaw K, et al. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. AIDS. 2012;26(7):861-865.
87. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18):2183-2189.
88. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, doseescalation study. Lancet Oncol. 2013;14(13): 1348-1356.